Secukinumab (anti-IL-17A)

製品コード：A2025 Batch: A202501

Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

製品説明

CAS No.	1229022-83-6
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	Human
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Purity	99.82%
Protein concentration	5.00mg/ml
Endotoxin Level	<1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Interleukin-17 regulates keratinocyte proliferation in psoriasis through the MALAT1/miR-125b/BRD4 axis [ American Scientific Publishers, 2024, 174-182(9)]	PubMed: None
Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway [ Signal Transduct Target Ther, 2022, 7(1):80]	PubMed: 35301282
Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice [ Biochem Pharmacol, 2021, 192:114728]	PubMed: 34400126

人間や獣医の診断であるか治療的な使用のためにでない。